News

Shares of beleaguered drug store and pharmacy chain Walgreens Boots Alliance (NASDAQ: WBA) fell 8.4% on Tuesday as of 3:22 p.m. ET.

The reason for the drop today appears to be twofold: One, Pfizer

With Pfizer (NYSE: PFE) stock badly underperforming the market over the past three years, falling by 32% while the market rose by close to the same amount, the last thing shareholders want to hear

Dividend stocks can be a great source of cash flow for your portfolio. You don't need to settle for stocks that pay just a few percentage points, either. Some fairly safe, high-yielding stocks pay

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently fell behind in their race with Moderna (NASDAQ: MRNA) to develop new combination shots that could be worth billions in annual sales. Top-line

Pharmaceutical giant Pfizer (NYSE: PFE) has been in a bit of a freefall since early 2022, with shares down by 46%. Pfizer's revenue and earnings dropped off a cliff along with its

In the thick of the coronavirus pandemic several years ago, any positive news from a developer of COVID-19 vaccines or drugs would have been met with a surge of buying in its stock. We're not in

The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions --

Would you like to improve your passive income stream but don't have a lot of extra cash to throw around? If so, I have great news: These days, $100 is all it takes to acquire a share of three top

While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022

Demand for COVID-19 vaccines and drugs has been fading for a while now. And that has put a big dent in Pfizer's (NYSE: PFE) sales and profit numbers. On top of that, the stock is also facing

The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4%

Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro

Pfizer (NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of

Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021.

However, the

Investors who buy stocks through both bull and bear markets are the ones who tend to benefit more in the long term because they are growing their portfolios consistently. But a bull market does seem

The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are